glp-1 patch clinical trial transdermal semaglutide patch Designing delivery: structural perspectives and formulation approaches for optimized therapy Do GLP-1 Patches Work? No

Community Clinic Observations Patient Tolerability Protocol: 15 patients escalated from 0.25 mg to 0.5 mg Observations: ~80 % remained on therapy at 12 weeks versus ~60 % retention in historical full-dose records

Prepregnancy GLP-1RA use improves maternal lipid metabolism via liver-secreted FGF21 during pregnancy in HFD-fed dams

Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023

My background is in formulation science, and I built this platform to bridge the gap between research and real-world skincare choices

Your journey stays between you and your doctor